Bristol-Myers Squibb Company (BMY)
NYSE: BMY · IEX Real-Time Price · USD
44.85
+0.15 (0.34%)
At close: Apr 26, 2024, 4:00 PM
44.90
+0.05 (0.11%)
After-hours: Apr 26, 2024, 7:59 PM EDT
BMY Employees
Bristol-Myers Squibb Company had 34,100 employees on December 31, 2023. The number of employees decreased by 200 or -0.58% compared to the previous year.
Employees
34,100
Change (1Y)
-200
Growth (1Y)
-0.58%
Revenue / Employee
$1,335,308
Profits / Employee
-$180,293
Market Cap
90.90B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 34,100 | -200 | -0.58% |
Dec 31, 2022 | 34,300 | 2,100 | 6.52% |
Dec 31, 2021 | 32,200 | 1,950 | 6.45% |
Dec 31, 2020 | 30,250 | 250 | 0.83% |
Dec 31, 2019 | 30,000 | 6,700 | 28.76% |
Dec 31, 2018 | 23,300 | -400 | -1.69% |
Dec 31, 2017 | 23,700 | -1,300 | -5.20% |
Dec 31, 2016 | 25,000 | 0 | - |
Dec 31, 2015 | 25,000 | 0 | - |
Dec 31, 2014 | 25,000 | -3,000 | -10.71% |
Dec 31, 2013 | 28,000 | 0 | - |
Dec 31, 2012 | 28,000 | 1,000 | 3.70% |
Dec 31, 2011 | 27,000 | 0 | - |
Dec 31, 2010 | 27,000 | -1,000 | -3.57% |
Dec 31, 2009 | 28,000 | -7,000 | -20.00% |
Dec 31, 2008 | 35,000 | -7,000 | -16.67% |
Dec 31, 2007 | 42,000 | -1,000 | -2.33% |
Dec 31, 2006 | 43,000 | 0 | - |
Dec 31, 2005 | 43,000 | 0 | - |
Dec 31, 2004 | 43,000 | -1,000 | -2.27% |
Dec 31, 2003 | 44,000 | 0 | - |
Dec 31, 2002 | 44,000 | -2,000 | -4.35% |
Dec 31, 2001 | 46,000 | 2,000 | 4.55% |
Dec 31, 2000 | 44,000 | -10,500 | -19.27% |
Dec 31, 1999 | 54,500 | -200 | -0.37% |
Dec 31, 1998 | 54,700 | 1,100 | 2.05% |
Dec 31, 1997 | 53,600 | 2,400 | 4.69% |
Dec 31, 1996 | 51,200 | 2,060 | 4.19% |
Dec 31, 1995 | 49,140 | 1,440 | 3.02% |
Dec 31, 1994 | 47,700 | -1,800 | -3.64% |
Dec 31, 1993 | 49,500 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
HCA Healthcare | 310,000 |
CVS Health | 300,000 |
Medtronic | 95,000 |
Cigna | 72,500 |
GSK | 70,212 |
Boston Scientific | 48,000 |
Gilead Sciences | 18,000 |
Zoetis | 14,100 |
BMY News
- 2 days ago - CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb's Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma - Business Wire
- 3 days ago - Bristol Myers Cuts Full-Year Earnings Forecast, Launches Cost Cuts - Barrons
- 3 days ago - Bristol Myers Squibb beats on revenue, launches $1.5 billion cost cuts as it posts quarterly loss - CNBC
- 3 days ago - Bristol Myers Squibb reports narrower-than-expected first-quarter loss, sales top estimates - Market Watch
- 3 days ago - Bristol Myers posts quarterly loss, revenue rises 5% - Reuters
- 3 days ago - Bristol Myers Squibb Reports First Quarter Financial Results for 2024 - Business Wire
- 6 days ago - Bristol Myers Squibb and Cellares reach $380 mln supply deal for CAR-T therapies - Reuters
- 6 days ago - Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to More Patients, Faster - Business Wire